Hidradenitis Suppurativa Market Size in the 7MM was ~USD 1400 Million in 2023 and it is expected to grow at a significant CAGR by 2036, according to DelveInsight

The Hidradenitis Suppurativa Market Size (7MM) was valued at ~USD 1400 Million in 2023 and is projected to grow at a robust CAGR during the study period (2022–2036). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Hidradenitis Suppurativa Market Landscape. By analyzing historical data, current Hidradenitis Suppurativa Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Hidradenitis Suppurativa Market is increasingly guided by biomarker-driven strategies. Hidradenitis Suppurativa is a chronic, painful skin condition characterized by the development of recurrent lumps, abscesses, and tunnels under the skin, typically occurring in areas where skin rubs together such as the armpits, groin, buttocks, and under the breasts. The disease occurs when hair follicles become blocked and inflamed, leading to painful nodules that may rupture and release pus, often resulting in scarring over time. Hidradenitis Suppurativa is considered a long-term inflammatory disorder and is associated with factors such as genetics, hormonal changes, smoking, and obesity.

DelveInsight’s report, “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2036,” provides a comprehensive analysis of the Hidradenitis Suppurativa Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Hidradenitis Suppurativa Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Hidradenitis Suppurativa Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Hidradenitis Suppurativa Market Forecast

Key Takeaways from Hidradenitis Suppurativa Market Report

• In 2023, the total Hidradenitis Suppurativa Prevalence Cases in the 7MM were nearly 6.2 million. These cases are anticipated to increase by 2036.
• In the 7MM, the US accounted for the highest number of Hidradenitis Suppurativa Diagnosed Prevalent Cases with nearly 877,600 in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa Diagnosed Prevalent Cases whereas Spain occupied the bottom of the ladder.
• In the US, EU4 and the UK, hidradenitis suppurativa was seen to be slightly more common in females (~75%) than males (~25%). Conversely, in Japan, males represent nearly 70% of the total cases, while females account for around 30%.
• The age-specific data revealed that hidradenitis suppurativa was most prevalent in the age group of 30–39 years, which was nearly 26% of the total diagnosed cases of hidradenitis suppurativa in the US.
• Among all, Hurley Stage I was observed to be most prevalent, with approximately 480,000 cases in 2023 in the US.
• The leading Hidradenitis Suppurativa Companies, such as Eli Lilly, AbbVie, MoonLake Immunotherapeutics, Priovant Therapeutics, Boehringer Ingelheim, UNION Therapeutics, Incyte Corporation, and others.
• Promising Hidradenitis Suppurativa Therapies such as Eltrekibart, Lutikizumab, Sonelokimab, Brepocitinib, Spesolimab, Orismilast, Povorcitinib, and others

Hidradenitis Suppurativa Overview

Hidradenitis Suppurativa is a long-term inflammatory skin condition characterized by painful, deep-seated lumps that develop under the skin, commonly in areas where skin rubs together such as the armpits, groin, buttocks, and under the breasts. The condition occurs when hair follicles become blocked and inflamed, leading to recurrent nodules, abscesses, and tunnels under the skin that may drain pus and cause scarring. Symptoms often include pain, swelling, redness, and persistent lesions that can recur over time. Although the exact cause is not fully understood, factors such as genetics, immune system dysfunction, hormonal influences, and lifestyle factors may contribute to its development. Hidradenitis Suppurativa can significantly affect a patient’s quality of life, and treatment typically involves medications to reduce inflammation, manage infections, and control symptoms, while severe cases may require surgical intervention.

Get a Free sample for the Hidradenitis Suppurativa Market Report @ https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market

Key Factors in Hidradenitis Suppurativa Therapeutics Market

• Rising Prevalence of Hidradenitis Suppurativa: The increasing number of diagnosed cases of hidradenitis suppurativa (HS), a chronic inflammatory skin disorder, is significantly driving the demand for effective therapeutic options worldwide.
• Growing Awareness and Early Diagnosis: Improved awareness among healthcare professionals and patients about HS symptoms and disease progression has led to earlier diagnosis and better treatment adoption.
• Advancements in Biologic Therapies: The development of targeted biologic therapies, particularly those focusing on inflammatory pathways such as TNF-alpha and interleukin inhibitors, is expanding treatment options and improving clinical outcomes for HS patients.
• Strong Drug Development Pipeline: Pharmaceutical companies are actively investing in research and development to introduce innovative therapies, including monoclonal antibodies and immunomodulatory, which are expected to strengthen the future treatment landscape.
• Increasing Healthcare Expenditure: Rising healthcare spending across major markets is enabling better access to advanced dermatology treatments and supporting the growth of the HS therapeutics market.
• Improved Clinical Research and Trials: A growing number of clinical trials focused on novel HS treatments is accelerating the development of new drugs and increasing opportunities for more effective disease management.
• Focus on Personalized Treatment Approaches: The growing emphasis on precision medicine and individualized treatment strategies is helping clinicians provide more targeted therapies based on patient-specific disease characteristics.

Hidradenitis Suppurativa Epidemiology Segmentation in the 7MM

The Hidradenitis Suppurativa Market Report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into-

• Total Prevalent Cases of Hidradenitis Suppurativa
• Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa
• Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa
• Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa
• Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa
• Treated Cases of Hidradenitis Suppurativa

Download the report to understand which factors are driving Hidradenitis Suppurativa Epidemiology trends @ Hidradenitis Suppurativa Epidemiology Forecast

Recent Development in the Hidradenitis Suppurativa Treatment Landscape

• In January 2026, MoonLake Immunotherapeutics provided an update following positive feedback from the US Food and Drug Administration (FDA) on the clinical evidence strategy for sonelokimab in hidradenitis suppurativa, following a Type B meeting requested by the company.
• In November 2025, MoonLake Immunotherapeutics announced key upcoming clinical milestones for sonelokimab in hidradenitis suppurativa. The company expects to report 52-week data from the Phase III VELA-1 and VELA-2 trials in adult hidradenitis suppurativa in Q2 2026. In addition, the primary endpoint readout from the Phase III VELA-TEEN trial, evaluating sonelokimab in adolescent patients with hidradenitis suppurativa, is anticipated in Q2 2026.
• In September 2025, Incyte presented new 24-week interim data evaluating the safety and efficacy of povorcitinib from the pivotal Phase III STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa at the European Association of Dermatology and Venereology (EADV) 2025 Congress.
• In March 2025, Incyte announced positive topline results from its pivotal Phase III STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib.

Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Hidradenitis Suppurativa drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched during the study period. The analysis covers Hidradenitis Suppurativa Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Hidradenitis Suppurativa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hidradenitis Suppurativa Therapies and Companies

• AVTX-009 Regimen 1: Avalo Therapeutics Inc.
• Izokibep:  ACELYRIN Inc.
• Remibrutinib: Novartis Pharmaceuticals
• Bimekizumab: UCB Biopharma SRL
• Ruxolitinib Cream: Incyte Corporation

To know more about Hidradenitis Suppurativa Companies working in the treatment market, visit @ Hidradenitis Suppurativa Clinical Trials and Therapeutic Assessment

Hidradenitis Suppurativa Market Drivers

• Increasing Prevalence of the Disease: The rising number of diagnosed cases of Hidradenitis Suppurativa is a key factor driving market growth, as more patients seek long-term treatment options to manage this painful and recurrent skin condition.
• Growing Awareness and Early Diagnosis: Increasing awareness among healthcare professionals and patients is improving early detection rates, which supports timely treatment and boosts the demand for effective therapeutic solutions.
• Advancements in Biologic Therapies: The development of targeted biologics and immunomodulatory drugs has significantly expanded treatment options for Hidradenitis Suppurativa, improving clinical outcomes and encouraging further research and innovation.
• Strong Pipeline of Emerging Therapies: Pharmaceutical companies are actively investing in research and development to introduce novel therapies, including monoclonal antibodies and targeted treatments, which is expected to enhance the future treatment landscape.
• Increasing Healthcare Expenditure: Rising healthcare spending across major markets is improving access to advanced dermatological treatments and supporting the adoption of innovative therapies
• Growing Focus on Personalized Medicine: Advances in precision medicine and targeted therapies are enabling more tailored treatment approaches for patients, improving treatment efficacy and patient satisfaction.

Hidradenitis Suppurativa Market Barriers

• Delayed Diagnosis and Misdiagnosis: Hidradenitis Suppurativa (HS) is often misdiagnosed or diagnosed late due to its symptoms being similar to other skin conditions such as boils or acne. This delay in diagnosis can slow the initiation of appropriate treatments and impact market growth.
• Limited Availability of Targeted Therapies: Despite growing research efforts, the number of approved targeted therapies for HS remains limited. Most currently available treatments focus on symptom management rather than addressing the underlying disease mechanisms.
• High Cost of Advanced Treatments: Biologic therapies used for moderate-to-severe HS can be expensive, which may limit patient access, particularly in regions with restricted healthcare coverage or limited reimbursement policies.
• Adverse Effects of Existing Therapies: Many HS treatments, including long-term antibiotics, immunosuppressants, and biologics, may lead to side effects that can affect patient adherence and long-term treatment use.
• Lack of Disease Awareness: In several regions, limited awareness about HS among patients and healthcare professionals contributes to underdiagnosis and delayed treatment, hindering the expansion of the treatment market.
• Complex Disease Management: HS is a chronic and recurrent condition that often requires a combination of medical therapy, lifestyle modifications, and surgical interventions, making treatment pathways more complicated.
• Challenges in Clinical Trial Recruitment: Recruiting suitable participants for clinical trials can be difficult due to strict eligibility criteria and the variable severity of the disease, which may slow the development of new therapies.

Scope of the Hidradenitis Suppurativa Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Hidradenitis Suppurativa Companies- Eli Lilly, AbbVie, MoonLake Immunotherapeutics, Priovant Therapeutics, Boehringer Ingelheim, UNION Therapeutics, Incyte Corporation, and others.
• Hidradenitis Suppurativa Therapies- Eltrekibart, Lutikizumab, Sonelokimab, Brepocitinib, Spesolimab, Orismilast, Povorcitinib, and others
• Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies
• Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers
• Hidradenitis Suppurativa Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hidradenitis Suppurativa Unmet Needs, KOL’s views, Analyst’s views, Hidradenitis Suppurativa Market Access and Reimbursement

Discover more about therapies set to grab the major Hidradenitis Suppurativa Market Share @ Hidradenitis Suppurativa Treatment Market

Table of Contents

1. Key Insights

2. Hidradenitis Suppurativa Market Report Introduction

3. Hidradenitis Suppurativa Executive Summary

4. Hidradenitis Suppurativa Key Events

5. Hidradenitis Suppurativa Epidemiology and Market Forecast Methodology

6. Hidradenitis Suppurativa Market Overview at a Glance

7. Hidradenitis Suppurativa Disease Background and Overview

8. Hidradenitis Suppurativa Epidemiology and Patient Population

9. Hidradenitis Suppurativa Patient Journey

10. Hidradenitis Suppurativa Marketed Drugs

11. Hidradenitis Suppurativa Emerging Drugs

12. Hidradenitis Suppurativa: 7MM Analysis

13. Hidradenitis Suppurativa Unmet Needs

14. Hidradenitis Suppurativa SWOT Analysis

15. Hidradenitis Suppurativa KOL Views

16. Hidradenitis Suppurativa Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.